MDNA — Medicenna Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$84.47m
- CA$54.65m
- 15
- 10
- 45
- 12
Annual cashflow statement for Medicenna Therapeutics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.28 | -17.3 | -22.6 | -10 | -25.5 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.107 | 1.26 | 0.799 | -5.02 | 8.46 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.793 | 0.68 | -1.84 | 2.41 | 0.741 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -8.95 | -15.3 | -23.6 | -12.7 | -16.3 |
| Other Investing Cash Flow Items | -15 | 5.01 | 10.1 | 0 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -15 | 5.01 | 10.1 | 0 | — |
| Financing Cash Flow Items | 3.54 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 44.3 | 18.3 | 3.88 | 24.8 | 0 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 20.3 | 7.68 | -9.84 | 13.1 | -16.6 |